热门资讯> 正文
MaxCyte与Adicet Bio签署平台许可协议
2025-08-04 20:57
- MaxCyte(MXCT) 0
- 艾切托(ACET) 0
- 纳比特(NA) 0
- MaxCyte (NASDAQ:MXCT) said on Monday that it has signed a strategic platform license with Adicet Bio, a biotechnology company focused on the development of allogeneic gamma delta T cell therapies for cancer and autoimmune diseases.
- Under the terms of the agreement, Adicet Bio will obtain non-exclusive research, clinical, and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform.
- In return, MaxCyte is entitled to receive platform licensing fees and program-related revenue.
More on MaxCyte
- MaxCyte, Inc. (MXCT) Q1 2025 Earnings Call Transcript
- MaxCyte GAAP EPS of -$0.10 beats by $0.01, revenue of $10.4M beats by $1.35M
- Seeking Alpha’s Quant Rating on MaxCyte
- Historical earnings data for MaxCyte
- Financial information for MaxCyte
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
